Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy
Abstract Background Apoptosis is a key pathologic feature in myocardial infarction and heart failure. Recent evidence suggests that statins may have beneficial effects on cardiovascular outcomes in patients with heart failure. The present study was planned to investigate the anti-apoptotic potential...
Gespeichert in:
| Veröffentlicht in: | International journal of cardiology 2011-07, Vol.150 (2), p.193-200 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 200 |
|---|---|
| container_issue | 2 |
| container_start_page | 193 |
| container_title | International journal of cardiology |
| container_volume | 150 |
| creator | Sharma, Himanshu Pathan, Rahila Ahmad Kumar, Vinay Javed, Saleem Bhandari, Uma |
| description | Abstract Background Apoptosis is a key pathologic feature in myocardial infarction and heart failure. Recent evidence suggests that statins may have beneficial effects on cardiovascular outcomes in patients with heart failure. The present study was planned to investigate the anti-apoptotic potential of rosuvastatin pretreatment in doxorubicin-induced cardiomyopathy. Methods Sixty male Wistar rats were randomly divided into six groups: Group-I (vehicle control group), Group-II (pathological Control group), Group-III (rosuvastatin 0.5 mg/kg), Group IV (rosuvastatin 2 mg/kg), Group-V (rosuvastatin 2 mg/kg per se ) , and Group-VI (carvedilol 1 mg/kg). Myocardial apoptosis was detected by caspase-3 assay, DNA gel electrophoresis and Na+ /K+ ATPase estimation. The animals were evaluated for various biochemical parameters in serum followed by histopathological studies of heart tissue. Results Doxorubicin treated rats exhibited cardiac dysfunctions as indicated by an increase in systolic, diastolic, mean BP, heart rate and tail blood flow and volume and increased serum LDH, TC, TGs, LDL-C, VLDL-C levels and atherogenic indexes. A marked induction in caspase-3 and Na+ -K+ ATPase levels and DNA laddering as revealed by agarose gel electrophoresis was observed in rat myocardium of pathological group. Pretreatment with the test drug, rosuvastatin significantly reduced the increase in hemodynamic parameters, serum LDH, lipid profile and myocardial caspase-3, Na+ -K+ ATPase activity as compared to the pathogenic control group. Further, DNA ladder formation was attenuated by rosuvastatin treatment. Histopathological studies further confirm its myocardial salvaging effects. The results were comparable with carvedilol. Conclusions The study demonstrates the cardioprotective potential of rosuvastatin against doxorubicin-induced myocardial apoptosis. |
| doi_str_mv | 10.1016/j.ijcard.2010.04.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_876187913</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0167527310002238</els_id><sourcerecordid>876187913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-78aecb6347996cde70aa5dd939bac4025688c4c7e09adc0971753921f65aa9ce3</originalsourceid><addsrcrecordid>eNqFkUuL1TAUgIMozp3RfyDSjbjqNUnTPDbCMIyOMOBCxWU4Nz3F1LapSTpw_72p96rgxlVI8p3Xdwh5weieUSbfDHs_OIjdntPyRMWeUv2I7JhWomaqFY_JrmCqbrlqLshlSgOlVBijn5ILTkXLqdQ78vV6zr6GJSw5ZO-qJWQsLzBWoa9iSOsDpAzZz9USMUeEPJX_qtynNfoZqyl0-AveevFhOoYF8rfjM_KkhzHh8_N5Rb68u_18c1fff3z_4eb6vnZCyFwrDegOshHKGOk6VBSg7TrTmAM4QXkrtXbCKaQGOkeNKpM1hrNetgDGYXNFXp_yLjH8WDFlO_nkcBxhxrAmq5UsRgxrCilOpCtjpYi9XaKfIB4to3Yzagd7Mmo3o5YKW4yWsJfnAuthwu5P0G-FBXh1BiA5GPsIs_PpLycaKbne6r89cVh0PHiMNjmPs8POR3TZdsH_r5N_E7jRz77U_I5HTENY41xUW2YTt9R-2ra_LZ-VvXPe6OYn-tasUQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>876187913</pqid></control><display><type>article</type><title>Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Sharma, Himanshu ; Pathan, Rahila Ahmad ; Kumar, Vinay ; Javed, Saleem ; Bhandari, Uma</creator><creatorcontrib>Sharma, Himanshu ; Pathan, Rahila Ahmad ; Kumar, Vinay ; Javed, Saleem ; Bhandari, Uma</creatorcontrib><description>Abstract Background Apoptosis is a key pathologic feature in myocardial infarction and heart failure. Recent evidence suggests that statins may have beneficial effects on cardiovascular outcomes in patients with heart failure. The present study was planned to investigate the anti-apoptotic potential of rosuvastatin pretreatment in doxorubicin-induced cardiomyopathy. Methods Sixty male Wistar rats were randomly divided into six groups: Group-I (vehicle control group), Group-II (pathological Control group), Group-III (rosuvastatin 0.5 mg/kg), Group IV (rosuvastatin 2 mg/kg), Group-V (rosuvastatin 2 mg/kg per se ) , and Group-VI (carvedilol 1 mg/kg). Myocardial apoptosis was detected by caspase-3 assay, DNA gel electrophoresis and Na+ /K+ ATPase estimation. The animals were evaluated for various biochemical parameters in serum followed by histopathological studies of heart tissue. Results Doxorubicin treated rats exhibited cardiac dysfunctions as indicated by an increase in systolic, diastolic, mean BP, heart rate and tail blood flow and volume and increased serum LDH, TC, TGs, LDL-C, VLDL-C levels and atherogenic indexes. A marked induction in caspase-3 and Na+ -K+ ATPase levels and DNA laddering as revealed by agarose gel electrophoresis was observed in rat myocardium of pathological group. Pretreatment with the test drug, rosuvastatin significantly reduced the increase in hemodynamic parameters, serum LDH, lipid profile and myocardial caspase-3, Na+ -K+ ATPase activity as compared to the pathogenic control group. Further, DNA ladder formation was attenuated by rosuvastatin treatment. Histopathological studies further confirm its myocardial salvaging effects. The results were comparable with carvedilol. Conclusions The study demonstrates the cardioprotective potential of rosuvastatin against doxorubicin-induced myocardial apoptosis.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2010.04.008</identifier><identifier>PMID: 20452068</identifier><identifier>CODEN: IJCDD5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Animals ; Apoptosis ; Apoptosis - drug effects ; Apoptosis - physiology ; Biological and medical sciences ; Biomarkers ; Cardiology. Vascular system ; Cardiomyopathies - chemically induced ; Cardiomyopathies - drug therapy ; Cardiomyopathies - pathology ; Cardiotonic Agents - administration & dosage ; Cardiovascular ; Disease Models, Animal ; Doxorubicin ; Doxorubicin - antagonists & inhibitors ; Doxorubicin - toxicity ; Fluorobenzenes - administration & dosage ; Heart ; Male ; Medical sciences ; Myocarditis. Cardiomyopathies ; Pyrimidines - administration & dosage ; Rats ; Rats, Wistar ; Rosuvastatin Calcium ; Statins ; Sulfonamides - administration & dosage</subject><ispartof>International journal of cardiology, 2011-07, Vol.150 (2), p.193-200</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2010 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-78aecb6347996cde70aa5dd939bac4025688c4c7e09adc0971753921f65aa9ce3</citedby><cites>FETCH-LOGICAL-c446t-78aecb6347996cde70aa5dd939bac4025688c4c7e09adc0971753921f65aa9ce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijcard.2010.04.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24366283$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20452068$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sharma, Himanshu</creatorcontrib><creatorcontrib>Pathan, Rahila Ahmad</creatorcontrib><creatorcontrib>Kumar, Vinay</creatorcontrib><creatorcontrib>Javed, Saleem</creatorcontrib><creatorcontrib>Bhandari, Uma</creatorcontrib><title>Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>Abstract Background Apoptosis is a key pathologic feature in myocardial infarction and heart failure. Recent evidence suggests that statins may have beneficial effects on cardiovascular outcomes in patients with heart failure. The present study was planned to investigate the anti-apoptotic potential of rosuvastatin pretreatment in doxorubicin-induced cardiomyopathy. Methods Sixty male Wistar rats were randomly divided into six groups: Group-I (vehicle control group), Group-II (pathological Control group), Group-III (rosuvastatin 0.5 mg/kg), Group IV (rosuvastatin 2 mg/kg), Group-V (rosuvastatin 2 mg/kg per se ) , and Group-VI (carvedilol 1 mg/kg). Myocardial apoptosis was detected by caspase-3 assay, DNA gel electrophoresis and Na+ /K+ ATPase estimation. The animals were evaluated for various biochemical parameters in serum followed by histopathological studies of heart tissue. Results Doxorubicin treated rats exhibited cardiac dysfunctions as indicated by an increase in systolic, diastolic, mean BP, heart rate and tail blood flow and volume and increased serum LDH, TC, TGs, LDL-C, VLDL-C levels and atherogenic indexes. A marked induction in caspase-3 and Na+ -K+ ATPase levels and DNA laddering as revealed by agarose gel electrophoresis was observed in rat myocardium of pathological group. Pretreatment with the test drug, rosuvastatin significantly reduced the increase in hemodynamic parameters, serum LDH, lipid profile and myocardial caspase-3, Na+ -K+ ATPase activity as compared to the pathogenic control group. Further, DNA ladder formation was attenuated by rosuvastatin treatment. Histopathological studies further confirm its myocardial salvaging effects. The results were comparable with carvedilol. Conclusions The study demonstrates the cardioprotective potential of rosuvastatin against doxorubicin-induced myocardial apoptosis.</description><subject>Animals</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis - physiology</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomyopathies - chemically induced</subject><subject>Cardiomyopathies - drug therapy</subject><subject>Cardiomyopathies - pathology</subject><subject>Cardiotonic Agents - administration & dosage</subject><subject>Cardiovascular</subject><subject>Disease Models, Animal</subject><subject>Doxorubicin</subject><subject>Doxorubicin - antagonists & inhibitors</subject><subject>Doxorubicin - toxicity</subject><subject>Fluorobenzenes - administration & dosage</subject><subject>Heart</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Pyrimidines - administration & dosage</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Rosuvastatin Calcium</subject><subject>Statins</subject><subject>Sulfonamides - administration & dosage</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUuL1TAUgIMozp3RfyDSjbjqNUnTPDbCMIyOMOBCxWU4Nz3F1LapSTpw_72p96rgxlVI8p3Xdwh5weieUSbfDHs_OIjdntPyRMWeUv2I7JhWomaqFY_JrmCqbrlqLshlSgOlVBijn5ILTkXLqdQ78vV6zr6GJSw5ZO-qJWQsLzBWoa9iSOsDpAzZz9USMUeEPJX_qtynNfoZqyl0-AveevFhOoYF8rfjM_KkhzHh8_N5Rb68u_18c1fff3z_4eb6vnZCyFwrDegOshHKGOk6VBSg7TrTmAM4QXkrtXbCKaQGOkeNKpM1hrNetgDGYXNFXp_yLjH8WDFlO_nkcBxhxrAmq5UsRgxrCilOpCtjpYi9XaKfIB4to3Yzagd7Mmo3o5YKW4yWsJfnAuthwu5P0G-FBXh1BiA5GPsIs_PpLycaKbne6r89cVh0PHiMNjmPs8POR3TZdsH_r5N_E7jRz77U_I5HTENY41xUW2YTt9R-2ra_LZ-VvXPe6OYn-tasUQ</recordid><startdate>20110715</startdate><enddate>20110715</enddate><creator>Sharma, Himanshu</creator><creator>Pathan, Rahila Ahmad</creator><creator>Kumar, Vinay</creator><creator>Javed, Saleem</creator><creator>Bhandari, Uma</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110715</creationdate><title>Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy</title><author>Sharma, Himanshu ; Pathan, Rahila Ahmad ; Kumar, Vinay ; Javed, Saleem ; Bhandari, Uma</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-78aecb6347996cde70aa5dd939bac4025688c4c7e09adc0971753921f65aa9ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis - physiology</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomyopathies - chemically induced</topic><topic>Cardiomyopathies - drug therapy</topic><topic>Cardiomyopathies - pathology</topic><topic>Cardiotonic Agents - administration & dosage</topic><topic>Cardiovascular</topic><topic>Disease Models, Animal</topic><topic>Doxorubicin</topic><topic>Doxorubicin - antagonists & inhibitors</topic><topic>Doxorubicin - toxicity</topic><topic>Fluorobenzenes - administration & dosage</topic><topic>Heart</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Pyrimidines - administration & dosage</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Rosuvastatin Calcium</topic><topic>Statins</topic><topic>Sulfonamides - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sharma, Himanshu</creatorcontrib><creatorcontrib>Pathan, Rahila Ahmad</creatorcontrib><creatorcontrib>Kumar, Vinay</creatorcontrib><creatorcontrib>Javed, Saleem</creatorcontrib><creatorcontrib>Bhandari, Uma</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sharma, Himanshu</au><au>Pathan, Rahila Ahmad</au><au>Kumar, Vinay</au><au>Javed, Saleem</au><au>Bhandari, Uma</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2011-07-15</date><risdate>2011</risdate><volume>150</volume><issue>2</issue><spage>193</spage><epage>200</epage><pages>193-200</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><coden>IJCDD5</coden><abstract>Abstract Background Apoptosis is a key pathologic feature in myocardial infarction and heart failure. Recent evidence suggests that statins may have beneficial effects on cardiovascular outcomes in patients with heart failure. The present study was planned to investigate the anti-apoptotic potential of rosuvastatin pretreatment in doxorubicin-induced cardiomyopathy. Methods Sixty male Wistar rats were randomly divided into six groups: Group-I (vehicle control group), Group-II (pathological Control group), Group-III (rosuvastatin 0.5 mg/kg), Group IV (rosuvastatin 2 mg/kg), Group-V (rosuvastatin 2 mg/kg per se ) , and Group-VI (carvedilol 1 mg/kg). Myocardial apoptosis was detected by caspase-3 assay, DNA gel electrophoresis and Na+ /K+ ATPase estimation. The animals were evaluated for various biochemical parameters in serum followed by histopathological studies of heart tissue. Results Doxorubicin treated rats exhibited cardiac dysfunctions as indicated by an increase in systolic, diastolic, mean BP, heart rate and tail blood flow and volume and increased serum LDH, TC, TGs, LDL-C, VLDL-C levels and atherogenic indexes. A marked induction in caspase-3 and Na+ -K+ ATPase levels and DNA laddering as revealed by agarose gel electrophoresis was observed in rat myocardium of pathological group. Pretreatment with the test drug, rosuvastatin significantly reduced the increase in hemodynamic parameters, serum LDH, lipid profile and myocardial caspase-3, Na+ -K+ ATPase activity as compared to the pathogenic control group. Further, DNA ladder formation was attenuated by rosuvastatin treatment. Histopathological studies further confirm its myocardial salvaging effects. The results were comparable with carvedilol. Conclusions The study demonstrates the cardioprotective potential of rosuvastatin against doxorubicin-induced myocardial apoptosis.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>20452068</pmid><doi>10.1016/j.ijcard.2010.04.008</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-5273 |
| ispartof | International journal of cardiology, 2011-07, Vol.150 (2), p.193-200 |
| issn | 0167-5273 1874-1754 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_876187913 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Apoptosis Apoptosis - drug effects Apoptosis - physiology Biological and medical sciences Biomarkers Cardiology. Vascular system Cardiomyopathies - chemically induced Cardiomyopathies - drug therapy Cardiomyopathies - pathology Cardiotonic Agents - administration & dosage Cardiovascular Disease Models, Animal Doxorubicin Doxorubicin - antagonists & inhibitors Doxorubicin - toxicity Fluorobenzenes - administration & dosage Heart Male Medical sciences Myocarditis. Cardiomyopathies Pyrimidines - administration & dosage Rats Rats, Wistar Rosuvastatin Calcium Statins Sulfonamides - administration & dosage |
| title | Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A06%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-apoptotic%20potential%20of%20rosuvastatin%20pretreatment%20in%20murine%20model%20of%20cardiomyopathy&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Sharma,%20Himanshu&rft.date=2011-07-15&rft.volume=150&rft.issue=2&rft.spage=193&rft.epage=200&rft.pages=193-200&rft.issn=0167-5273&rft.eissn=1874-1754&rft.coden=IJCDD5&rft_id=info:doi/10.1016/j.ijcard.2010.04.008&rft_dat=%3Cproquest_cross%3E876187913%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=876187913&rft_id=info:pmid/20452068&rft_els_id=1_s2_0_S0167527310002238&rfr_iscdi=true |